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a b s t r a c t
Background: Ideal rescue treatments for acute treatment of seizure clusters should be easy to administer,
so it is important to assess user perceptions of these treatments. Diazepam nasal spray is designed to
have a rapid, noninvasive, and socially acceptable route of administration. Patient and caregiver (including care partner) responses to surveys from a phase 3 safety study of diazepam nasal spray are reported.
Methods: The study enrolled patients aged 6–65 years with seizure clusters. Surveys distributed to
patients and caregivers at study end, completion, or discontinuation collected data on comfort using diazepam nasal spray outside the home, timing of administration and return to their usual selves, and comfort of use compared with rectal diazepam. Safety was assessed.
Results: Of 175 patients enrolled at the October 31, 2019, interim cutoff, 158 received diazepam nasal
spray. Sixty-seven (42.4%) patients and 84 (53.2%) caregivers responded to the surveys (including 35
matched pairs). Most patients (78.8%, 52/66) responded that they were very comfortable doing activities
outside the home with diazepam nasal spray available; 59.4% of patients returned to their usual selves
within an hour of administration. Twenty-seven (40.3%) of these patients reported self-administration,
48% doing so at the first sign of a seizure. Administration of diazepam nasal spray was rated extremely
or very easy by 93.8% of caregivers. Safety profile was consistent with diazepam rectal gel; no patient discontinued owing to treatment-emergent adverse events. Nasal discomfort was typically mild and transient. Among patients who had used diazepam rectal gel, most were not at all comfortable using it
outside the home (86.7%) or at home (64.5%) compared with diazepam nasal spray, whereas caregivers
reported that diazepam rectal gel was not at all easy to use compared with diazepam nasal spray.
Conclusions: This survey from the phase 3 safety study of diazepam nasal spray shows that patients and
caregivers were satisfied with, and more comfortable using, diazepam nasal spray than rectal diazepam
in public.
NCT02721069.
Ó 2021 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction
Seizure clusters are intermittent, recognizable stereotypic episodes of seizure activity that are distinct from a patient’s usual seizures [1]. Rescue therapy for seizure clusters has generally relied

Abbreviations: TEAE, treatment-emergent adverse event.
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E-mail address: ppenovich@mnepilepsy.net (P. Penovich).

on benzodiazepines as first-line treatment [2,3]. Most seizure clusters occur outside the hospital environment [4]; therefore, ideal
rescue treatments for patients with epilepsy experiencing seizure
clusters should be easy for patients and caregivers (including care
partners such as family members and school personnel) to access
and administer in the community setting.
Although rectal diazepam has long been approved for treatment
of seizure clusters outside the hospital, this route of administration
may be considered socially unacceptable by some patients and

https://doi.org/10.1016/j.yebeh.2021.108013
1525-5050/Ó 2021 The Author(s). Published by Elsevier Inc.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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physical examination or electrocardiogram during screening.
Female patients of childbearing potential were required to use an
approved method of birth control. Patient history of status epilepticus or allergic rhinitis and current concomitant benzodiazepine
use were permitted to best ensure an inclusive, relevant realworld population, which also allowed for evaluation of safety
and effectiveness of diazepam nasal spray in these patients. Key
exclusion criteria were history of major depression or a past suicide attempt or suicidal ideation; history of allergy or adverse
response to diazepam; and history of a clinically significant medical condition that would jeopardize the safety of the patient. This
trial was conducted in accordance with the principles outlined in
the Declaration of Helsinki, and institutional review board
approval (main board: Western Institutional Review Board,
Puyallup, WA) was obtained before study initiation. All patients
provided written informed consent to participate.

caregivers [2]. Without access to a more acceptable route of
administration, patients who decline rectal therapy for seizure
clusters may require admission to an emergency department. It
is therefore important to assess user perceptions of rescue treatments to identify those that are more likely to be used, thereby
reducing the potential for emergency department visits or hospitalization. Understanding the impact of seizure clusters on patients
and caregivers may aid in enhancing management of the disease
[5]. To promote self-management by patients, physicians should
consider quality-of-life concerns when treating patients with
refractory epilepsy [6].
Diazepam nasal spray (ValtocoÒ) is a proprietary intranasal formulation approved by the US Food and Drug Administration for the
acute treatment of intermittent, stereotypic episodes of frequent
seizure activity (i.e., seizure clusters, acute repetitive seizures) in
patients with epilepsy aged 6 years and older [7]. It is designed
to provide a rapid, noninvasive, and socially acceptable route of
administration. Diazepam nasal spray includes IntravailÒ A3 as
an absorption enhancer and vitamin E to assist with solubility.
For orphan drug exclusivity, the US Food and Drug Administration
found that the intranasal route was clinically superior compared to
rectal administration because it provides a major contribution to
patient care by significantly improving ease of use and being more
comfortable and easier to administer [8]. Diazepam nasal spray is
designed to be portable and ready to use. The intranasal device
provides a specified metered dose with ease of use in one hand
and fitting easily inside a handbag or backpack, allowing for selfadministration in patients who can participate in their own treatment. The safety and tolerability of diazepam nasal spray has been
assessed in a phase 3, long-term, open-label safety study of
patients with epilepsy.
A survey to understand patients’ and caregivers’ opinions of diazepam nasal spray as rescue therapy was included in the phase 3
study. The objective of the present analyses was to assess patient
and caregiver responses to the survey regarding timing of administration of diazepam nasal spray, ease of administration, and comfort using this formulation outside of the home. Perceptions of
diazepam nasal spray in subgroups who self-administered and
who previously used diazepam rectal gel also were examined.

2.3. Study outcomes
The primary study objective was safety, including assessments
of treatment-emergent adverse events (TEAEs; irrespective of relationship to study drug). All TEAEs were coded according to the
Medical Dictionary for Regulatory Activities and graded according
to the Common Terminology Criteria for Adverse Events v.4.03.
Based on investigator assessment, TEAEs were categorized as
unlikely, possibly, or probably treatment related. Serious TEAEs
were reported per investigator assessment and defined as per
International Council for Harmonisation Guidelines for Good
Clinical Practice (i.e., those resulting in death or are life threatening, those requiring inpatient hospitalization or prolongation of
hospitalization, those resulting in persistent or significant disability/incapacity, or those considered important medical events).
Results are reported descriptively.
2.4. Patient and caregiver surveys
The surveys were provided to all patients enrolled in the study
and their caregivers; caregivers and patients on the study at the
time were given surveys at one time point toward the end of the
study, to be returned at the next visit, and the surveys were mailed
to those who had already completed or discontinued the study.
Surveys were developed by the study investigators and an expert
panel of epileptologists treating adult or pediatric patients to
assess various facets of the patient and caregiver experiences,
including comfort using diazepam nasal spray outside the home,
timing of administration and return to their usual selves, and convenience of use compared with rectal diazepam (Supplemental
Figs. 1 and 2) and received face validation prior to use but were
not evaluated for construct validity. Surveys were provided in
paper format with true/false or multiple-choice questions;
responses were subsequently entered into the database. Patient
and caregiver results were tabulated separately; cases in which
both the patient and their caregiver responded to the survey were
also evaluated as patient–caregiver matched pairs. Patients and
caregivers were not required to answer every survey question.
Responders received nominal compensation ($50 gift card) for
their time.

2. Methods
2.1. Study design and dosing
Diazepam nasal spray was evaluated in a phase 3, repeat-dose,
open-label, long-term safety study (NCT02721069) of patients
with epilepsy who have seizure clusters despite use of a stable regimen of antiseizure drugs. The study consisted of a screening
phase, baseline, 12-month treatment period, and 28-day followup period; at the discretion of the investigator, patients could continue treatment beyond day 365. Patients received age- and
weight-based doses of 5, 10, 15, or 20 mg of diazepam nasal spray.
A second dose could be administered 4–12 h after the first dose if
needed. Both patients and caregivers were trained in proper
administration. Patient diaries were used to record seizures and
diazepam nasal spray administration.
2.2. Patients

2.5. Statistical analysis

Patients aged 6–65 years with a diagnosis of either partial or
generalized epilepsy with motor seizures or seizures with clear
alteration of awareness were enrolled in the study. Additional
key inclusion criteria were availability of a qualified caregiver or
medical professional to administer study medication and no clinically significant abnormal findings in their medical history, or on

Statistical analysis was performed using Fisher’s exact test on
the patient and caregiver responses regarding satisfaction with
diazepam nasal spray (Question 23, Suppl Fig. 1 and Question 26,
Suppl Fig. 2, respectively) to determine overall impact of age group
(<18 vs 18 years) and dose (5, 10, 15, and 20 mg) on the selected
responses.
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respondents, respectively. Only 1 patient (5.3%) reported that it
was not at all easy to train others.
Among 53 patients who had had prior rescue medication protocols before starting this study, 32 (60.4%) reported prior administration of rectal diazepam. Of the 31 patients with safety data
who reported prior use of rectal diazepam, the median age was
14 years (range, 7–51 years; 6–<12 years, n = 7; 12–18 years,
n = 15; >18 years, n = 9). Compared with diazepam nasal spray,
86.7% of patients were not at all comfortable having rectal diazepam administered in public, and 64.5% were not at all comfortable
having their caregiver administer rectal diazepam at home. When
considering treatment convenience, 83.9% (26/31) would prefer
using diazepam nasal spray exclusively going forward.
Among patient respondents, 87.9% reported they or their caregivers carried diazepam nasal spray outside the home; 84.5% of
patients were extremely or very comfortable carrying it with them,
and 78.8% of patients were very comfortable doing activities outside the home if they had diazepam nasal spray available. After
the most recent time they administered diazepam nasal spray,
the majority of patients returned to their usual selves within 1 h
(59.4%; Fig. 2). The majority of patients (53/66; 80.3%) reported
being very satisfied or satisfied with diazepam nasal spray, and
were either extremely (39/64; 60.9%) or very (11/64; 17.2%) likely
to ask the patient’s healthcare provider about continuing diazepam
nasal spray.
Of the 66 patients who responded to the survey and had available safety data, 51 (77.3%) reported a TEAE. Seventeen patients
(25.8%) had a serious TEAE, none of which was considered by the
investigator to be treatment related (2 patients: seizure [13.6%],
pneumonia [4.5%]). No patient discontinued because of a TEAE.
Four mild and 1 moderate report of nasal discomfort were all
assessed as treatment related.

3. Results
3.1. Safety population
Overall, 175 patients had enrolled in the phase 3 study by the
October 31, 2019, interim cutoff date; of these, 158 received a total
of 3724 doses of diazepam nasal spray for 3370 reported clusters
and were included in the safety population. The remaining 17
patients did not receive study drug. Approximately 53.8% of
patients in the safety population were female, and the median
age was 19.5 years. The majority of patients (73.4%) had 12 or more
months of exposure to diazepam nasal spray (median,
13.0 months; range, <1–36.6 months). Treatment-related TEAEs
were only reported in 26 patients (16.5%); there were no serious
treatment-related TEAEs and no discontinuations due to TEAEs.
The retention rate in this long-term study was 83% (i.e., 27 patients
discontinued). At the time of the analysis, 47 patients had already
completed the study, and surveys were mailed to their last known
addresses as well as to patients who had discontinued. Not all
questions were answered by all patients or all caregivers; thus,
the denominators differ for some questions.

3.2. Patient survey
Sixty-seven patients responded to the survey; of these, 66 had
safety data and were included in the safety set (Fig. 1). Of these
patients, 47.0% were female, the median age was 24.5 years, and
78.8% had median diazepam nasal spray treatment duration of a
year or more (Table 1). At the data cutoff, 22 patients had completed the study, 5 had discontinued, and 39 were ongoing.
Among the patients who responded, 19 trained another person
to use diazepam nasal spray. In total, 48 individuals were trained
by patients. People trained included both parents (n = 6), grandparents (n = 1), siblings (n = 5), friends (n = 8), and other (n = 28).
Training others to use diazepam nasal spray was rated as either
extremely easy or very easy by 42.1% (8/19) and 47.4% (9/19)

3.2.1. Patient survey: patients self-administering diazepam nasal spray
A subset (n = 27) of the patients reported self-administering
diazepam nasal spray. Of these patients, the median age was 34
(range, 11–65) years, 55.6% were female, and 96.3% had a treatment duration of a year or more (Table 2). Seizure types and subtypes were not consistently reported for these patients but
included complex partial (focal onset impaired awareness), simple
partial (focal onset aware), absence, generalized tonic-clonic, and
myoclonic.
Doses administered were 10 mg (n = 2 [7.4%]), 15 mg (n = 10
[37.0%]), and 20 mg (n = 15 [55.6%]); no patient in this group
received the 5-mg dose. Of the 3724 doses administered in the
safety population, 994 (26.7%) doses were administered in this
subgroup (10 mg, n = 61 [6.1%]; 15 mg, n = 180 [18.1%]; and
20 mg, n = 753 [75.8%]). Of the 27 patients, 3 (11.1%) used 1 to 2
doses, 4 (14.8%) each used 3 to 10 or 11 to 20 doses, and 8
(29.6%) each used 21 to 40 or >40 doses during the study. There
was a low rate of dosing errors in the self-administering patient
subgroup (11 [1.1%]), primarily missing the nostril and initially
misunderstanding directions (e.g., missing half of a dose if 2
devices are required for dose), compared with 1.0% (27 errors in
2641 doses) among patients in the survey population who did
not self-administer and 1.5% in safety population of the overall
study.
Self-administering patients were asked when they primarily
administered diazepam nasal spray (Fig. 3). The most common
response was, ‘‘At the first signs that a seizure may be coming”
(48.0%, n = 12). Twenty-one respondents (77.8%) reported that
self-administration of diazepam nasal spray was either extremely
easy (n = 11) or very easy (n = 10). The majority of patients
(n = 18; 66.7%) reported that self-administering diazepam nasal
spray in a public setting was either extremely (n = 5), very
(n = 3), or somewhat (n = 10) comfortable.

Fig. 1. Flowchart of responses to surveys.
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Table 1
Baseline Characteristics of Patient Survey Respondents (Safety Population; n = 66).
Demographics
n (%)
Sex
Male
Female
Race
White
Black or African American
Asian
Native Hawaiian or other Pacific Islander
Other
Age, y
Median
Range
Duration of exposure
<6 mo
6–<12 mo
12 mo

5 mg
(n = 1)

10 mg
(n = 18)

15 mg
(n = 20)

20 mg
(n = 27)

Total
(n = 66)

0
1 (100)

11 (61.1)
7 (38.9)

9 (45.0)
11 (55.0)

15 (55.6)
12 (44.4)

35 (53.0)
31 (47.0)

1 (100)
0
0
0
0

12 (66.7)
2 (11.1)
2 (11.1)
0
2 (11.1)

16 (80.0)
2 (10.0)
0
1 (5.0)
1 (5.0)

22 (81.5)
2 (7.4)
0
2 (7.4)
1 (3.7)

51 (77.3)
6 (9.1)
2 (3.0)
3 (4.5)
4 (6.1)

26.0
26–26

11.5
7–65

24.0
12–54

35.0
11–59

24.5
7–65

0
1 (100.0)
0

1 (5.6)
7 (38.9)
10 (55.6)

0
2 (10.0)
18 (90.0)

0
3 (11.1)
24 (88.9)

1 (1.5)
13 (19.7)
52 (78.8)

no serious TEAE was considered treatment related. No patient in
this subgroup discontinued owing to a TEAE.
3.2.2. Caregiver survey
Eighty-four caregivers of enrolled patients responded to the
survey (Fig. 1, Table 3). Of the 83 caregivers who responded to
the question regarding their relationship to the patient, 100% were
family members. Demographically, 85.2% (69/81) were female and
65.9% (54/82) were aged 31–50 years (median, 47 years; range, 29–
73 years). Most caregivers (64/84; 76.2%) reported a post–high
school education level (college, graduate school, or trade program).
Of the 83 respondents to the question, 61 (73.5%) considered it
extremely easy to be trained to administer diazepam nasal spray
and 22 (26.5%) reported that it was very easy; no respondent considered it not at all easy. Sixty-eight caregivers trained another
person to use diazepam nasal spray; 2 of the 68 caregivers did
not answer this question, but did respond to the question of whom
they trained. In total, 250 persons were trained by caregivers. The
median (range) number of persons trained by an individual caregiver was 3 (1–15). Persons trained included both parents
(n = 50), grandparents (n = 34), siblings (n = 26), friends (n = 29),
teachers (n = 45), and other (n = 66). Training others to use diazepam nasal spray was rated as either extremely easy or very easy
by 40 and 28 respondents, respectively.

Fig. 2. Timing to return to usual for patients after the most recent administration of
diazepam nasal spray. Sixty-four patients responded to the survey question. Bars
represent percentage of patients who chose that answer.

The safety profile of the self-administering patients was similar
to the full patient survey respondent population. In this subgroup,
20 patients (74.1%) had a TEAE. Six patients (22.2%) had TEAEs that
were possibly treatment related. Only nasal discomfort (n = 4,
14.8% [3 mild, 1 moderate]) was reported in 2 patients. Six
patients (22.2%) in this subgroup had a serious TEAE. However,

Table 2
Baseline Characteristics of Patient Survey Respondents Who Reported Self-Administering of Diazepam Nasal Spray (Safety Population; n = 27).
Demographics*
n (%)
Sex
Male
Female
Race
White
Black or African American
Asian
Native Hawaiian or other Pacific Islander
Other
Age, y
Median
Range
Duration of exposurey
6–<12 mo
12 mo
Number of dosesà

10 mg
(n = 2)

15 mg
(n = 10)

20 mg
(n = 15)

Total
(n = 27)

1 (50.0)
1 (50.0)

5 (50.0)
5 (50.0)

6 (40.0)
9 (60.0)

12 (44.4)
15 (55.6)

1 (50.0)
0
1 (50.0)
0
0

8 (80.0)
1 (10.0)
0
0
1 (10.0)

13 (86.7)
0
0
1 (6.7)
1 (6.7)

22 (81.5)
1 (3.7)
1 (3.7)
1 (3.7)
2 (7.4)

38.0
11–65

25.5
16–54

38.0
22–59

34.0
11–65

0
2 (100.0)
61

1 (10.0)
9 (90.0)
180

0
15 (100.0)
753

1 (3.7)
26 (96.3)
994

*None of the patients reporting self-administration were in the 5-mg dose group.
None of the patients reporting self-administration had a duration of exposure <6 months.
This is the total number of self-administered doses in this group over the duration of the open-label study.

y

à

4

Epilepsy & Behavior 121 (2021) 108013

P. Penovich, J.W. Wheless, R. Edward Hogan et al.

(67/83; 80.7%), primarily rectal diazepam (57/68; 83.8%). Although
the vast majority of caregivers (76/81; 93.8%) considered administration of diazepam nasal spray to be extremely or very easy, use of
diazepam rectal gel was rated not at all easy by 64.3% (36/56) in
comparison to diazepam nasal spray. Only 4 (7.1%) caregivers rated
diazepam rectal gel administration to be extremely easy or very
easy. Most caregivers carried diazepam nasal spray outside the
home (80/82; 97.6%) and considered it extremely or very comfortable to carry with them (76/81; 93.8%). The majority of caregivers
were extremely or very comfortable (69/77; 89.6%) using diazepam
nasal spray in a public setting. In contrast, 87.0% (47/54) of caregivers were not at all comfortable using rectal diazepam gel in a
public setting. The majority of caregivers (77/83; 92.8%) reported
being very satisfied or satisfied with diazepam nasal spray, and
were either extremely (64/84; 76.2%) or very (13/84; 15.5%) likely
to ask the patient’s healthcare provider about continuing diazepam
nasal spray in the future.
Safety data were available for 76 patients (90.5%) whom these
caregivers assisted; some of these patients (n = 35) were also
included in the analysis of patient–caregiver matched pairs, below.
Treatment-emergent adverse events occurred in 61 patients
(80.3%). A total of 26 patients (34.2%) had a serious TEAE; none
were treatment related. No patients discontinued owing to a TEAE.

Fig. 3. Primary timing of administration of diazepam nasal spray by patients who
self-administered doses. Twenty-five patients responded to the survey question.
Bars represent percentage of patients who chose that answer.
Table 3
Caregiver Demographics (Survey Responders; n = 84).
Characteristic
Caregiver type
Family caregiver
Professional caregiver
No answer
Gender
Male
Female
Nonbinary/third gender
No answer
Age, median, y (range)
18–30
31–40
41–50
51–60
61–70
71–80
No answer
Highest education level
Elementary school
Less than high school (middle school)
High school
College
Graduate school
Trade program
Prior use of seizure rescue medications, yes
Diazepam rectal gel
Patient age
Child (6–11 y)
Adolescent (12–17 y)
Adult (18 y)
Number of doses administered to patients

n (%)
83 (98.8)
0 (0)
1 (1.2)

3.2.3. Patient–caregiver matched pairs
There were 35 cases in which both the patient and caregiver
individually responded to the survey (Fig. 1). Five (14.3%) of these
patients were also included in the self-administration analysis
described above. The majority of respondents said the caregiver
previously administered rectal diazepam before use of diazepam
nasal spray (patients, 77.4% [24/31]; caregivers, 81.5% [22/27]).
When asked about the timing of administration of diazepam nasal
spray, results were similar to the larger patient and caregiver
groups for when diazepam nasal spray was primarily administered. The majority of patients who self-administered (3/5;
60.0%) reported administering diazepam nasal spray at the first
sign of a seizure. The majority of caregivers (26/32; 81.3%) reported
administering diazepam nasal spray either during a cluster of seizures or when they were repeating, only during a seizure, or most
of the time during a seizure.
Both patients and caregivers reported on the ease of use of diazepam nasal spray. All patients reported that diazepam nasal spray
was either extremely easy, very easy, or somewhat easy to selfadminister, and the same was true for 97.1% (33/34) of the caregivers. Only 1 caregiver responded that diazepam nasal spray
administration was not at all easy to use. Patients and caregivers
were also asked about the ease of use of diazepam rectal gel versus
diazepam nasal spray. Again, responses were similar for patients
and caregivers. The majority of patients who previously received
rectal diazepam responded that it was not at all easy (16/24;
66.7%) for their caregiver to administer versus diazepam nasal
spray. Similarly, 59.1% (13/22) of caregivers who previously
administered rectal diazepam responded that it was not at all easy
to administer versus diazepam nasal spray. Compared with diazepam nasal spray, caregivers (16/20; 80.0%) reported that administration of diazepam rectal gel was not at all comfortable and
patients (19/22; 86.4%) found it not at all comfortable to have diazepam rectal gel administered in public.
When asked about their treatment preference (vs rectal diazepam) based on treatment convenience, responses from patients
and caregivers were again similar. The majority of both patients
(21/24; 87.5%) and caregivers (29/33; 87.9%) responded that they
would prefer to exclusively use diazepam nasal spray moving forward. Responses to the questions related to the time to return to
usual self or usual activities after administering diazepam nasal
spray were similar to the responses to these questions for the over-

12 (14.3)
69 (82.1)
0 (0)
3 (3.6)
47 (29–73)
2 (2.4)
24 (28.6)
30 (35.7)
14 (16.7)
10 (11.9)
2 (2.4)
2 (2.4)
1 (1.2)
3 (3.6)
16 (19.0)
47 (56.0)
14 (16.7)
3 (3.6)
67 (79.8)
57 (85.1)*
36 (42.9)
26 (30.9)
22 (26.2)
2641

*Of the 67 caregivers who reported prior use of rescue medications.

The majority of caregivers (62/82; 75.6%) reported administering diazepam nasal spray to the patient either all (35/82; 42.7%)
or two thirds of the time (27/82; 32.9%). Caregivers were asked
when they primarily administered diazepam nasal spray to the
patient. Caregiver-reported timing of primary administration of
diazepam nasal spray was most commonly during a seizure cluster
(Fig. 4A). Administration of diazepam nasal spray was rated
extremely, very, or somewhat easy by 54.3% (44/81), 39.5%
(32/81), and 4.9% (4/81) of caregivers, respectively, whereas 1 caregiver considered administration to be not at all easy. The majority
of caregivers self-assessed that they (the caregivers themselves)
could return to their own daily activities within an hour after the
most recent administration of diazepam nasal spray to the patient
(47/79; 59.5%; Fig. 4B).
The patients of these caregivers received 2641 doses of diazepam nasal spray. Most caregivers reported having administered a
seizure rescue medication to the patient before this study
5
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A

B

Fig. 4. Administration of diazepam nasal spray by caregivers. A, Timing of administration. B, Amount of time to return to daily activities after most recent administration. Of
caregivers who responded to the survey question, the bars represent percentage who chose that answer.

zure rescue medication protocol before diazepam nasal spray
study entry, most were prescribed diazepam rectal gel. Of note,
caregivers reported that diazepam nasal spray was easier to
administer than diazepam rectal gel, and both patients and caregivers were more comfortable with administration of diazepam
nasal spray in public compared with rectal diazepam. These findings suggest that patients and their caregivers found that diazepam
nasal spray was a beneficial treatment option.
A prior cross-sectional survey also investigated attitudes
toward the use of intranasal midazolam and rectal diazepam as
rescue therapy for seizure clusters in caregivers of young (ages
0–23 years) patients with epilepsy who received treatment at a
tertiary level IV epilepsy center and large academic medical institution [9]. Of the caregivers who reported administering both formulations, the majority preferred intranasal midazolam to rectal
diazepam: 87% considered it to be more effective, and 74% felt
more comfortable with it [9]. Compared with rectal diazepam,
intranasal midazolam was viewed as having fewer side effects,
was easier to train others to use, and was more readily available
at school [9]. That prior study had some differences from the
present study: the patients were generally younger (average age,
10.5 years [range, 3–22] and 24.5 years [range, 7–65], respectively), and patient preferences were not assessed in the earlier
study. Despite these differences, these findings complement those
of the current study and provide further evidence of the preference
of caregivers for intranasal versus rectal formulations of benzodiazepines to treat seizure clusters outside a hospital setting.
The results among patients who self-administered diazepam
nasal spray support a potential benefit of this approach over other
routes of administration that require a caregiver. Diazepam nasal
spray is administered with a device similar to that used for some
self-administered intranasal therapies, such as for migraine headaches [10]. The potential for self-administration of intranasal benzodiazepine rescue therapy for seizure clusters may provide
patients with more control over their treatment. In the surveys,
self-administering patients—some as young as 11 years old—
reported ease of use of diazepam nasal spray, and their safety profile was consistent with the entire study population. Importantly,
there were very few self-dosing errors. Overall, these findings support the use of self-administered diazepam nasal spray in a manner
consistent with the prescribing information.
In cases in which both patient and caregiver responded to the
survey (n = 35), paired responses tended to be similar overall. Both
groups considered diazepam nasal spray to be convenient to carry
and easy to use. Moreover, both groups preferred diazepam nasal
spray to rectal diazepam gel, especially for use in a public setting.
Both groups indicated that they were satisfied with diazepam nasal

all groups of patients and caregivers. Normal activities were able to
be resumed in <1 h by 27.3% (9/33) of patients, in 1–2 h by 30.3%
(10/33) of patients, and in >2 h by 42.4% (10/33) of patients. Normal activities were able to be resumed in <1 h by 48.5% (16/33)
of caregivers, in 1 –2 h by 30.3% of caregivers, and in >2 h by
21.2% of caregivers. Both patients (28/35, 80.0%) and caregivers
(32/35, 91.4%) indicated that they were either very satisfied or satisfied with diazepam nasal spray.
Safety data were available for 33 of the patients in the matched
pairs. Treatment-emergent adverse events occurred in 25 patients
(75.8%). Eleven patients (33.3%) had a serious TEAE; none were
treatment related. No patients discontinued owing to a TEAE.
3.3. Statistical analysis results
Patient and caregiver responses were analyzed regarding satisfaction with diazepam nasal spray by age and dose. Patient and
caregiver age groups (<18 and 18 years) did not show statistical
significance relative to the satisfaction responses (overall
P = 0.8135 and P = 0.4084, respectively). The same was true for
patient and caregiver dose groups of 5, 10, 15, and 20 mg (overall
P = 0.3450 and P = 0.5263, respectively).
4. Discussion
Seizure clusters can place significant emotional and financial
burdens on both patients with epilepsy and their caregivers [5].
Although diazepam rectal gel has been approved for decades for
the treatment of seizure clusters, patients and caregivers report
that it can be difficult to administer and socially unacceptable to
use in public [2,3]. The availability of a rescue medication that is
easy to use, convenient to carry, and socially acceptable to use in
public may help patients and their caregivers choose to use rescue
therapy instead of relying on hospitalization in the event of a seizure cluster. Thus, it is of great importance to assess patient and
caregiver perceptions of treatment.
This analysis reports results from a survey of patients enrolled
in the phase 3 safety study of diazepam nasal spray and their caregivers. Overall, both patients and caregivers had positive impressions of diazepam nasal spray. Patients and caregivers found
diazepam nasal spray comfortable to carry and use outside the
home; most were able to return to their usual self or daily activities
in <1 h (patients, 59.4%; caregivers, 59.5%, respectively). A subgroup of self-treating patients reported that treatment was most
commonly administered at the first sign of a seizure. Caregivers
reported primarily administering diazepam nasal spray during a
seizure cluster. Of the patients who were prescribed another sei6
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spray and would prefer to use this formulation as rescue therapy in
the future. These findings are important because they suggest that
diazepam nasal spray would improve the quality of life and reduce
burdens for both patients and their caregivers. Furthermore, the
ease of use of diazepam nasal spray may result in increased use
of rescue therapy during a seizure cluster, possibly reducing the
need for emergency care.
For all survey groups, safety of the patients was consistent with
that of the established profile of rectal diazepam, with no discontinuations due to TEAEs or unexpected TEAEs. No serious TEAEs
were deemed treatment related for any of the subgroups of
patients analyzed. Nasal discomfort was transient and typically
mild.
This analysis is subject to some limitations. To our knowledge,
this is one of the largest populations in a clinical study of rescue
medication for seizure clusters, capturing the highest number of
seizure events. These results are based on a subset of respondents,
and the overall response rates for patients and caregivers of 48%
compares favorably with response rates of about half to a quarter
in other patient/caregiver surveys [11–13]. As such, they may be
subject to self-selection, and responses may not be generalizable
to the broad population of patients who experience seizure clusters
in the real world or their caregivers. Because of the nature of surveys, verification of individual responses for internal consistency
was not possible; however, the overall results show a high degree
of consistency among patients and among caregivers as well as
between patient and caregiver responses. Overall, there are few
data on how patients and caregivers view rescue therapy for seizure clusters, and these results from a large open-label study provide novel information on this topic.
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5. Conclusions
The responses from this survey demonstrate that patients and
caregivers find diazepam nasal spray easy to administer and use
outside the home. Moreover, a subgroup of patients, aged 11–
65 years, were able to take an active role in their own treatment
and reported ease of use with self-administration. Caregivers
reported administration mainly during seizures. Of note, patients
and caregivers who previously used rectal diazepam as a rescue
therapy protocol strongly preferred the convenience of diazepam
nasal spray. These results suggest that administration of diazepam
nasal spray may provide patients and caregivers with more control
of their treatment and daily routine.
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